Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a ...

A trial of Sanofi’s new eczema drug has disappointed investors hoping for a replacement for its blockbuster Dupixent, sending the French pharma group’s shares down more than 9 per cent on Thursday.

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Kymera Therapeutics (KYMR) stock rises as RBC Capital Markets starts coverage with an Outperform recommendation, citing potential of lead drug KT-621. Read more here.

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its ...

Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and ...